RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
78 hedge funds and large institutions have $468M invested in RAPT Therapeutics in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 9 closing their positions.
376% more call options, than puts
Call options by funds: $16.6M | Put options by funds: $3.49M
16% more capital invested
Capital invested by funds: $404M → $468M (+$64.4M)
0.19% more ownership
Funds ownership: 10.41% → 10.61% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
4% less funds holding
Funds holding: 81 → 78 (-3)
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$18.5M |
| 2 |
Millennium Management
New York
|
+$1.53M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$1.44M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$931K |
| 5 |
Two Sigma Advisers
New York
|
+$530K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.33M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$2.52M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$992K |
| 4 |
Morgan Stanley
New York
|
-$728K |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$610K |
RAPT Hedge Fund Activity: Q1 2021 in Review
78 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2021, worth a combined $468M — up 16% from $404M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RAPT and 6 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 19 added.
The largest buyer was Perceptive Advisors, adding an estimated $18.5M. The largest seller was Wellington Management Group, cutting an estimated $4.33M.
- 78 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2021, down from 81 in Q4 2020.
- Funds reported $468M of RAPT Therapeutics stock for Q1 2021, up 16% quarter-over-quarter.
- 6 funds opened new RAPT Therapeutics positions in Q1 2021 and 9 closed out, a net change of -3 holders.
- The largest RAPT Therapeutics buyer in Q1 2021 was Perceptive Advisors, an estimated $18.5M added.
- The largest RAPT Therapeutics seller in Q1 2021 was Wellington Management Group, an estimated $4.33M sold.
Based on aggregated 13F filings for Q1 2021.